학술논문
Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
Document Type
Academic Journal
Author
O'Connor D; UCL Cancer Institute, University College London, London, United Kingdom.; Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.; Valle-Inclán JE; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom.; Conde L; UCL Cancer Institute, University College London, London, United Kingdom.; Bloye G; UCL Cancer Institute, University College London, London, United Kingdom.; Rahman S; UCL Cancer Institute, University College London, London, United Kingdom.; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.; Costa JR; UCL Cancer Institute, University College London, London, United Kingdom.; Bartram J; Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.; Adams S; Specialist Integrated Haematology and Malignancy Diagnostic Service-Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.; Wright G; Specialist Integrated Haematology and Malignancy Diagnostic Service-Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.; Elrick H; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom.; Wall K; West Midlands Regional Genetics Laboratory, Birmingham, United Kingdom.; Dyer S; West Midlands Regional Genetics Laboratory, Birmingham, United Kingdom.; Howell C; Alder Hey Children's Hospital, Liverpool, United Kingdom.; Jigoulina G; Southampton Children's Hospital, Southampton, United Kingdom.; Herrero J; UCL Cancer Institute, University College London, London, United Kingdom.; Cortes-Ciriano I; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom.; Moorman AV; Leukaemia Research Cytogenetics Group, Wolfson Childhood Cancer Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; Mansour MR; UCL Cancer Institute, University College London, London, United Kingdom.; Department of Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Subject
Language
English
Abstract
Abstract: T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy.
(© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
(© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)